Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis

详细信息    查看全文

• 作者：Eiichi Ogawa^a ; Norihiro Furusyo^a ; Hideyuki Nomura^b ; Kazuhiro Takahashi^c ; Nobuhiko Higashi^d ; Akira Kawano^e ; Kazufumi Dohmen^f ; Takeaki Satoh^g ; Koichi Azuma^h ; Makoto Nakamutaⁱ ; Toshimasa Koyanagi^j ; Masaki Kato^k ; Shinji Shimoda^l ; Eiji Kajiwara^m ; Jun Hayashiⁿ ; ^{hayashij1949@haradoi-hospital.com} ; The Kyushu University Liver Disease Study (KULDS) Group
• 关键词：Hepatitis C virus ; Gerontology ; Cirrhosis ; Sofosbuvir ; Ribavirin ; DAA
• 刊名：Antiviral Research
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：136
• 期：Complete
• 页码：37-44
• 全文大小：797 K
• 卷排序：136

文摘

The SVR12 rate of patients aged ≥65 was 95.3% in sofosbuvir plus ribavirin for HCV genotype 2. For treatment-experienced patients, cirrhosis undermined the treatment outcome, both for the aged ≥65 and < 65 groups. Early virological response was associated with a low baseline HCV RNA level, but not with treatment outcome. The most common adverse effect was anemia, especially for older patients with the ITPA CC genotype at rs1127354. Ribavirin reduction and mean dosage of ribavirin had little impact on treatment failure.